Author: admin

How Hoss Design USA’s AI Solutions Can Enhance Business Efficiency

“A sample of an invention for business with the help of AI”
Hoss Design USA offers custom AI solutions for business improvement. Their AI tools enhance customer service, streamline operations, boost marketing efforts, and innovate product development.

Artificial Intelligence (AI) solutions are revolutionizing the way businesses operate. From enhancing customer service to optimizing operations, AI can significantly improve various aspects of your business. Here’s how AI solutions can drive your business forward:

Enhancing Customer Service

AI solutions can transform customer service. Chatbots and virtual assistants provide 24/7 support. They can handle common queries, freeing up human agents for complex issues. This leads to quicker response times and higher customer satisfaction.

Personalization is another benefit. AI can analyze customer data to offer personalized recommendations. This improves customer experience and boosts sales. Imagine a virtual assistant that remembers your preferences and tailors its suggestions accordingly.

AI-driven customer service tools also gather valuable feedback. They analyze interactions to identify areas for improvement. This continuous learning process ensures that your customer service keeps getting better.

Streamlining Operations

AI solutions can optimize your operations. Predictive analytics help in forecasting demand and managing inventory. This reduces waste and ensures you have the right products at the right time. Efficient inventory management is a game-changer.

Automation is a key advantage. AI can automate repetitive tasks, freeing up employees to focus on strategic activities. From data entry to report generation, automation enhances productivity and reduces errors. Your team can achieve more in less time.

AI also enhances decision-making. By analyzing vast amounts of data, AI provides insights that help in making informed decisions. Whether it’s market trends or customer preferences, AI delivers actionable insights that drive business growth.

Boosting Marketing Efforts

AI solutions can take your marketing to the next level. They analyze consumer behavior to identify trends and preferences. This allows for highly targeted marketing campaigns. Personalized ads resonate better with audiences, leading to higher conversion rates.

Social media marketing benefits from AI as well. AI tools can identify trending topics and create engaging content. They offer content creation and marketing solutions to determine the best times to post on Instagram and YouTube for maximum reach. Your social media presence becomes more dynamic and effective.

AI also aids in email marketing. It can segment your audience and tailor messages to each segment. Personalized emails have higher open rates and engagement. AI ensures your marketing efforts are data-driven and results-oriented.

Data analysis is a powerful aspect of AI in marketing. AI can analyze vast amounts of data to uncover patterns and insights. This helps in understanding customer behavior and preferences. With this information, marketing strategies can be continuously improved. Campaigns become more effective, and ROI increases.

Innovating Product Development

AI solutions can revolutionize product development. They assist in designing and prototyping products quickly and accurately. Need a prototype made? AI tools make the process efficient and precise. From 3D design to prototype printing, AI ensures high-quality results.

Product research is enhanced with AI. It analyzes market trends and consumer feedback to guide product development. You can create products that meet market demands and exceed customer expectations. AI-driven innovation keeps you ahead of the competition.

Hoss Design USA is an example of a company excelling with AI. They have significantly improved their business using AI solutions, from marketing and product design to prototyping solutions. Hoss Design USA leverages AI to stay ahead. They not only optimize their operations but also provide AI solutions to help other businesses thrive.

AI also speeds up the time-to-market. By automating parts of the development process, AI reduces the time it takes to launch new products. Faster innovation cycles mean you can respond to market changes more effectively.

Improving Financial Management

AI solutions can improve financial management. They automate bookkeeping and accounting tasks, ensuring accuracy and efficiency. AI-driven financial tools analyze spending patterns and identify cost-saving opportunities.

Risk management benefits from AI as well. AI algorithms can detect fraudulent activities and predict potential risks. This proactive approach minimizes losses and enhances financial security.

AI also aids in financial forecasting. By analyzing historical data and market trends, AI provides accurate financial forecasts. This helps in budgeting and strategic planning. Your financial decisions become more informed and effective.

Media Contact
Company Name: Hoss Design USA LLC
Email: Send Email
Country: United States
Website: https://hossdesignusa.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: How Hoss Design USA\’s AI Solutions Can Enhance Business Efficiency

Asthma Clinical Trials Analysis 2024: Therapies, FDA Approvals, Mechanism of Action, Route of Administration, and Companies by DelveInsight

“Asthma Clinical Trials”
Asthma companies are Mabpharm Limited, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and others.

(Albany, USA) Asthma Pipeline Insight offers in-depth analysis of over 90+ companies and more than 100+ pipeline medications within the Asthma treatment landscape.

DelveInsight’s ‘Asthma Pipeline Insight 2024’ report provides comprehensive global coverage of available, marketed, and pipeline asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the asthma pipeline domain.

 

To know more about the Asthma pipeline report, click here @ Asthma Pipeline Analysis

 

Key Takeaways from the Asthma Pipeline Report

  • DelveInsight’s asthma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for asthma treatment. 
  • Leading asthma companies such as Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others are evaluating new asthma drugs to improve the treatment landscape.
  • Emerging asthma pipeline therapies in various stages of development include CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.
  • On February 2024, AstraZeneca announced results of a Prospective, Observational, Real-World Evidence Study (ASCENT): Asthma Control in Severe Asthma Patients Treated With Tezepelumab.
  • On November 2023, Regeneron Pharmaceuticals announced results of a study whose aim is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life.
  • On February 2024, AstraZeneca announced results of a Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics.
  • On November 2023, GlaxoSmithKline announced results of a 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
  • In February 2023, UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development. Dexpramipexole is beig developed by Areteia Therapeutics to inhibit the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels.

 

Request a sample and discover the recent advances in asthma drug treatment @ Asthma Treatment Market

 

Asthma Overview

Asthma is a chronic disease of the airways. Asthma is characterized by airway inflammation and spasm. Airways are tubes that transport air into and out of the lungs. Asthmatics cause the inside walls of the airways to become sore and swollen. Because of inflammation and tightening of the muscles surrounding the small airways, the airways in the lungs become narrow. Asthma symptoms include coughing, wheezing, shortness of breath, and chest tightness. Asthma symptoms differ from person to person. A person may have infrequent asthma attacks, have symptoms only when exercising, or have symptoms all of the time. Asthma symptoms are similar to those of many respiratory infections. 

A careful clinical history is the first step in asthma diagnosis; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on quality of life.

 

Find out more about drugs for asthma @ Asthma Therapies and Drugs

 

Asthma Pipeline Drugs mentioned in the report:

  • MM09-MG01: Inmunotek S.L.
  • BGF MDI: AstraZeneca
  • GSK3511294: GlaxoSmithKline
  • FP 025: Foresee Pharmaceuticals
  • ADX-629: Aldeyra Therapeutics
  • 610: Sunshine Guojian Pharmaceutical
  • EDP1867: Evelo Biosciences, Inc.
  • CM-326 : Keymed Biosciences
  • 9MW1911: Mabwell (Shanghai) Bioscience Co., Ltd.
  • Dapansutrile: Olatec Therapeutics
  • LNR 125.38: Lanier Biotherapeutics

 

Learn more about the emerging asthma pipeline therapies @ Asthma Clinical Trials and FDA Approval

 

Asthma Therapeutics Assessment

The asthma pipeline report proffers an integral view of asthma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Scope of the Asthma Pipeline Report 

  • Coverage: Global 
  • Key Asthma Companies: Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others.
  • Key Asthma Pipeline Therapies: CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.

 

Dive deep into rich insights for new drugs for asthma treatment; visit @ Asthma Therapeutic Assessment

 

Table of Contents

1. Asthma Pipeline Report Introduction

2. Asthma Pipeline Report Executive Summary

3. Asthma Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Asthma Clinical Trial Therapeutics

6. Asthma Pipeline: Late Stage Products (Pre-registration)

7. Asthma Pipeline: Late Stage Products (Phase III)

7.1.BGF MDI: AstraZeneca

8. Asthma Pipeline: Mid Stage Products (Phase II)

8.1. GSK3511294: GlaxoSmithKline

9. Asthma Pipeline: Early Stage Products (Phase I)

9.1. CM-326: Keymed Biosciences

10. Asthma Pipeline Therapeutics Assessment

11. Inactive Products in the Asthma Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Asthma Companies

14. Key Products in the Asthma Pipeline

15. Asthma Unmet Needs

16. Asthma Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asthma Clinical Trials Analysis 2024: Therapies, FDA Approvals, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Pyelonephritis Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

“Pyelonephritis Clinical Trials”
Pyelonephritis companies are Wockhardt, Sinovent, Entasis Therapeutics, Melinta Therapeutics, Allecra Therapeutics GmbH, Entasis Therapeutics Holdings Inc, Iterum Therapeutics Plc, Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd, Merck & Co Inc, MerLion Pharmaceuticals Pte Ltd, Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc, Pfizer Inc, Qilu Pharmaceutical Co Ltd, VenatoRx Pharmaceuticals Inc, XuanZhu Biological Technology Co Ltd and others.

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pyelonephritis pipeline constitutes 20+ key companies continuously working towards developing 20+ Pyelonephritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Pyelonephritis Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pyelonephritis Market.

The Pyelonephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Request for Sample Report here @ Pyelonephritis Pipeline Analysis

 

Some of the key takeaways from the Pyelonephritis Pipeline Report:

  • Pyelonephritis Companies across the globe are diligently working toward developing novel Pyelonephritis treatment therapies with a considerable amount of success over the years. 
  • Pyelonephritis companies working in the treatment market are Wockhardt, Sinovent, Entasis Therapeutics, Melinta Therapeutics, Allecra Therapeutics GmbH, Entasis Therapeutics Holdings Inc, Iterum Therapeutics Plc, Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd, Merck & Co Inc, MerLion Pharmaceuticals Pte Ltd, Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc, Pfizer Inc, Qilu Pharmaceutical Co Ltd, VenatoRx Pharmaceuticals Inc, XuanZhu Biological Technology Co Ltd and others, are developing therapies for the Pyelonephritis treatment.
  • Emerging Pyelonephritis therapies such as WCK-5222, XNW 4107, ETX2514SUL and others are expected to have a significant impact on the Pyelonephritis market in the coming years.
  • On December 2023, Wockhardt announced results of a Phase 3, Randomized, Double-blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults.
  • On June 2023, Meiji Seika Pharma Co., Ltd announced results of a Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults.

 

Pyelonephritis Overview

Pyelonephritis is a bacterial infection of the kidneys, typically stemming from a urinary tract infection (UTI) that ascends to the kidneys. It commonly affects women and can occur suddenly (acute pyelonephritis) or develop gradually (chronic pyelonephritis). The most common causative agent is Escherichia coli, though other bacteria can also be responsible.

Symptoms of pyelonephritis may include fever, chills, flank pain (pain in the side or back), nausea, vomiting, and frequent urination. In severe cases, individuals may experience confusion or symptoms of sepsis, a life-threatening condition characterized by systemic inflammation in response to infection.

Pyelonephritis Diagnosis typically involves a physical examination, urinalysis, urine culture, and imaging studies such as ultrasound, CT scan, or MRI to assess kidney involvement and rule out complications like abscess formation or kidney stones.

Pyelonephritis Treatment often involves antibiotics to eradicate the bacterial infection. In severe cases or those involving complications, hospitalization may be necessary for intravenous antibiotic therapy and supportive care. Adequate hydration is important to help flush out bacteria from the urinary tract. Patients may also require pain management and medications to alleviate fever and discomfort.

Untreated or recurrent pyelonephritis can lead to complications such as kidney damage, abscess formation, sepsis, or even kidney failure, emphasizing the importance of prompt diagnosis and treatment. Additionally, preventive measures such as good hygiene, proper hydration, and prompt treatment of UTIs can help reduce the risk of developing pyelonephritis.

 

Get a Free Sample PDF Report to know more about Pyelonephritis Pipeline Therapeutic Assessment- Pyelonephritis Treatment Market

 

Pyelonephritis Route of Administration

Pyelonephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Pyelonephritis Molecule Type

Pyelonephritis Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Pyelonephritis Pipeline Therapeutics Assessment

  • Pyelonephritis Assessment by Product Type
  • Pyelonephritis By Stage and Product Type
  • Pyelonephritis Assessment by Route of Administration
  • Pyelonephritis By Stage and Route of Administration
  • Pyelonephritis Assessment by Molecule Type
  • Pyelonephritis by Stage and Molecule Type

 

DelveInsight’s Pyelonephritis Pipeline Report covers around 20+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Pyelonephritis product details are provided in the report. Download the Pyelonephritis pipeline report to learn more about the emerging Pyelonephritis therapies- Pyelonephritis Clinical Trials and FDA Approvals

 

Pyelonephritis Pipeline Analysis:

The Pyelonephritis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pyelonephritis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pyelonephritis Treatment.
  • Pyelonephritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Pyelonephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pyelonephritis market.

 

Download Sample PDF Report to know more about Pyelonephritis drugs and therapies- Pyelonephritis Clinical Trials and FDA Approvals

 

Scope of Pyelonephritis Pipeline Drug Insight    

  • Coverage: Global
  • Key Pyelonephritis Companies: Wockhardt, Sinovent, Entasis Therapeutics, Melinta Therapeutics, Allecra Therapeutics GmbH, Entasis Therapeutics Holdings Inc, Iterum Therapeutics Plc, Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd, Merck & Co Inc, MerLion Pharmaceuticals Pte Ltd, Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc, Pfizer Inc, Qilu Pharmaceutical Co Ltd, VenatoRx Pharmaceuticals Inc, XuanZhu Biological Technology Co Ltd and others.
  • Key Pyelonephritis Therapies: WCK-5222, XNW 4107, ETX2514SUL and others.
  • Pyelonephritis Therapeutic Assessment: Pyelonephritis current marketed and Pyelonephritis emerging therapies
  • Pyelonephritis Market Dynamics: Pyelonephritis market drivers and Pyelonephritis market barriers 

 

Request for Sample PDF Report for Pyelonephritis Pipeline Assessment and clinical trials – Pyelonephritis Therapeutics Market

 

Table of Contents

1. Pyelonephritis Report Introduction

2. Pyelonephritis Executive Summary

3. Pyelonephritis Overview                

4. Pyelonephritis- Analytical Perspective In-depth Commercial Assessment

5. Pyelonephritis Pipeline Therapeutics

6. Pyelonephritis Late Stage Products (Phase II/III)

7. Pyelonephritis Mid Stage Products (Phase II)

8. Pyelonephritis Early Stage Products (Phase I)

9. Pyelonephritis Preclinical Stage Products

10. Pyelonephritis Therapeutics Assessment

11. Pyelonephritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pyelonephritis Companies

14. Pyelonephritis Key Products

15. Pyelonephritis Unmet Needs

16 . Pyelonephritis Market Drivers and Barriers

17. Pyelonephritis Future Perspectives and Conclusion

18. Pyelonephritis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pyelonephritis Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

“Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials”
Non Alcoholic Fatty Liver Disease (NAFLD) companies are Eli Lilly and Company, AstraZeneca, Oasis Pharmaceuticals, LLC, BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Terns, Hepion Pharmaceuticals, Poxel, Galectin Therapeutics, AngioLabs, MediciNova and others.

(Albany, United States) As per DelveInsight’s assessment, globally, Non Alcoholic Fatty Liver Disease (NAFLD) pipeline constitutes 80+ key companies continuously working towards developing 100+ Non Alcoholic Fatty Liver Disease (NAFLD) treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non Alcoholic Fatty Liver Disease (NAFLD) Market.

The Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Request for Sample Report here @ Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis

 

Some of the key takeaways from the Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Report:

  • NAFLD Companies across the globe are diligently working toward developing novel Non Alcoholic Fatty Liver Disease (NAFLD) treatment therapies with a considerable amount of success over the years. 
  • Non Alcoholic Fatty Liver Disease (NAFLD) companies working in the treatment market are Eli Lilly and Company, AstraZeneca, Oasis Pharmaceuticals, LLC, BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Hepion Pharmaceuticals, Poxel, Galectin Therapeutics, AngioLabs, MediciNova and others, are developing therapies for the Non Alcoholic Fatty Liver Disease (NAFLD) treatment.
  • Emerging Non Alcoholic Fatty Liver Disease (NAFLD) therapies such as MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others are expected to have a significant impact on the Non Alcoholic Fatty Liver Disease (NAFLD) market in the coming years.
  • On April 2024, Akero Therapeutics, Inc announced results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • On December 2023, Madrigal Pharmaceuticals, Inc announced results of a 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

 

Non Alcoholic Fatty Liver Disease (NAFLD) Overview

Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition characterized by the accumulation of fat in the liver of individuals who consume little to no alcohol. NAFLD encompasses a spectrum of liver conditions, ranging from simple fatty liver (steatosis) to more severe forms like non-alcoholic steatohepatitis (NASH), which involves inflammation and liver cell damage. Risk factors for NAFLD include obesity, insulin resistance, type 2 diabetes, high cholesterol, and metabolic syndrome. The exact cause of NAFLD is not fully understood but is believed to involve a combination of genetic, environmental, and lifestyle factors.

NAFLD often presents without noticeable symptoms in its early stages, but as the condition progresses, individuals may experience fatigue, abdominal discomfort, and enlargement of the liver. Diagnosis typically involves imaging studies such as ultrasound, CT scan, or MRI, along with blood tests to assess liver function and rule out other liver diseases.

Management of NAFLD primarily focuses on lifestyle interventions, including weight loss, regular exercise, and dietary changes aimed at reducing fat accumulation in the liver and improving metabolic health. For individuals with NASH or advanced NAFLD, additional treatments such as medications targeting liver inflammation or fibrosis may be considered. Close monitoring and management of NAFLD are essential to prevent progression to more severe liver complications, including cirrhosis and liver failure.

 

Get a Free Sample PDF Report to know more about Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Therapeutic Assessment @ Non Alcoholic Fatty Liver Disease (NAFLD) Treatment Market

 

Non Alcoholic Fatty Liver Disease (NAFLD) Route of Administration

Non Alcoholic Fatty Liver Disease (NAFLD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Non Alcoholic Fatty Liver Disease (NAFLD) Molecule Type

Non Alcoholic Fatty Liver Disease (NAFLD) Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Therapeutics Assessment

  • Non Alcoholic Fatty Liver Disease (NAFLD) Assessment by Product Type
  • Non Alcoholic Fatty Liver Disease (NAFLD) By Stage and Product Type
  • Non Alcoholic Fatty Liver Disease (NAFLD) Assessment by Route of Administration
  • Non Alcoholic Fatty Liver Disease (NAFLD) By Stage and Route of Administration
  • Non Alcoholic Fatty Liver Disease (NAFLD) Assessment by Molecule Type
  • Non Alcoholic Fatty Liver Disease (NAFLD) by Stage and Molecule Type

 

DelveInsight’s Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Report covers around 100+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Non Alcoholic Fatty Liver Disease (NAFLD) product details are provided in the report. Download the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline report to learn more about the emerging Non Alcoholic Fatty Liver Disease (NAFLD) therapies @ Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials and FDA Approvals

 

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis:

The Non Alcoholic Fatty Liver Disease (NAFLD) pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non Alcoholic Fatty Liver Disease (NAFLD) with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Alcoholic Fatty Liver Disease (NAFLD) Treatment.
  • Non Alcoholic Fatty Liver Disease (NAFLD) key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Non Alcoholic Fatty Liver Disease (NAFLD) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Alcoholic Fatty Liver Disease (NAFLD) market.

 

Download Sample PDF Report to know more about Non Alcoholic Fatty Liver Disease (NAFLD) drugs and therapies @ Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market

  

Scope of Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Drug Insight    

  • Coverage: Global
  • Key Non Alcoholic Fatty Liver Disease (NAFLD) Companies: Eli Lilly and Company, AstraZeneca, Oasis Pharmaceuticals, LLC, BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Hepion Pharmaceuticals, Poxel, Galectin Therapeutics, AngioLabs, MediciNova and others.
  • Key Non Alcoholic Fatty Liver Disease (NAFLD) Therapies: MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others.
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutic Assessment: Non Alcoholic Fatty Liver Disease (NAFLD) current marketed and Non Alcoholic Fatty Liver Disease (NAFLD) emerging therapies
  • Non Alcoholic Fatty Liver Disease (NAFLD) Market Dynamics: Non Alcoholic Fatty Liver Disease (NAFLD) market drivers and Non Alcoholic Fatty Liver Disease (NAFLD) market barriers 

 

Request for Sample PDF Report for Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Assessment and clinical trials @ Non Alcoholic Fatty Liver Disease (NAFLD) Drugs and Therapies

 

Table of Contents

  1. Non Alcoholic Fatty Liver Disease (NAFLD) Report Introduction
  2. Non Alcoholic Fatty Liver Disease (NAFLD) Executive Summary
  3. Non Alcoholic Fatty Liver Disease (NAFLD) Overview       
  4. Non Alcoholic Fatty Liver Disease (NAFLD)- Analytical Perspective In-depth Commercial Assessment
  5. Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Therapeutics
  6. Non Alcoholic Fatty Liver Disease (NAFLD) Late Stage Products (Phase II/III)
  7. Non Alcoholic Fatty Liver Disease (NAFLD) Mid Stage Products (Phase II)
  8. Non Alcoholic Fatty Liver Disease (NAFLD) Early Stage Products (Phase I)
  9. Non Alcoholic Fatty Liver Disease (NAFLD) Preclinical Stage Products
  10. Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Assessment
  11. Non Alcoholic Fatty Liver Disease (NAFLD) Inactive Products
  12. Company-University Collaborations (Licensing/Partnering) Analysis
  13. Non Alcoholic Fatty Liver Disease (NAFLD) Companies
  14. Non Alcoholic Fatty Liver Disease (NAFLD) Key Products
  15. Non Alcoholic Fatty Liver Disease (NAFLD) Unmet Needs
  16. 16 . Non Alcoholic Fatty Liver Disease (NAFLD) Market Drivers and Barriers
  17. Non Alcoholic Fatty Liver Disease (NAFLD) Future Perspectives and Conclusion
  18. Non Alcoholic Fatty Liver Disease (NAFLD) Analyst Views
  19. Appendix
  20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

The Dairy Alliance and Publix Fuel Runners at Peachtree Health & Fitness Expo

The Dairy Alliance and Publix Fuel Runners at Peachtree Health & Fitness Expo
Provides attendees with nutrient-rich and refreshing dairy milk at Peachtree Health & Fitness Expo

The Dairy Alliance, a nonprofit funded by dairy farmers in the Southeast, is teaming up with Publix to hydrate and fuel up runners at the Peachtree Health & Fitness Expo presented by Publix at the Georgia World Congress Center in Atlanta. The Dairy Alliance will distribute over 6,000 bottles of chocolate dairy milk, generously provided by Publix. Attendees are encouraged to visit The Dairy Alliance exhibit in Hall C4 at Booth #410 from July 2 to 3, 2024, between 10 a.m. and 6 p.m.

Research supports that dairy milk is one of the best beverages for hydration, outperforming water, and sports drinks. The Dairy Alliance’s team members will be onsite to educate attendees firsthand about dairy milk’s hydration benefits leading up to the AJC Peachtree Road Race on July 4.

“We are thrilled to be working with Publix again and supporting runners as they prepare for the world’s largest 10K race,” Geri Berdak, Chief Executive Officer at The Dairy Alliance. “Our focus is to help all 60,000 plus runners have their best day through the powerful benefits of dairy milk which includes hydration and recovery, and we are honored to be part of such a significant event in the Atlanta area.”

Expo attendees are invited to connect with Marie Spano, MS, RD, CSCS, CSSD, a renowned sports nutritionist and nutrition communications expert. Spano will be a panelist at this year’s Expo where attendees can meet her at The Dairy Alliance Booth #410 in person.

“This is an excellent opportunity for attendees to discover how dairy milk can support their peak performance and recovery,” said Spano. “I’m looking forward to speaking on this year’s panel and representing The Dairy Alliance as we connect with runners leading up to race day.”

The Expo will be open to the public, where attendees can stop by and grab a complimentary bottle of refreshing chocolate milk, cooling towels, cowbells, and stickers.

The AJC Peachtree Road Race is part of the lead-up to Every Woman’s Marathon, an initiative by MilkPEP. The Dairy Alliance is dedicated to supporting women and their races. Join #TEAMMILK by signing up for Every Woman’s Marathon as a runner or supporter.

Learn more at https://everywomansmarathon.com. For more information about The Dairy Alliance, visit https://thedairyalliance.com or follow them on Facebook or Instagram @TheDairyAlliance.

About The Dairy Alliance

The Dairy Alliance is a nonprofit funded by the Southeast dairy farm families. We work diligently with dairy farmers, schools, sports teams, health professionals, local organizations, state leaders, the media, and the public to promote dairy foods and knowledge about the dairy industry. Our efforts centre in eight states: Alabama, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, and Virginia.

Social Media:

Facebook: @thedairyalliance

Instagram:@thedairyalliance/

LinkedIn: https://www.linkedin.com/company/thedairyalliance/ 

Media Contact
Company Name: Ink Link Marketing
Contact Person: Kaitlyn Ianiro
Email: Send Email
Phone: 305.631.2283
City: Sioux Falls
State: South Dakota
Country: United States
Website: http://www.nekterjuicebar.com/

CRYPTOMMS LTD. (CRYPTOMMS EXCHANGE cryptomms.com) has recently successfully filed with the SEC and launched multiple public welfare projects

Renowned company CRYPTOMMS LTD. recently completed a successful filing with the U.S. Securities and Exchange Commission (SEC) and obtained the Reg D exemption. CRYPTOMMS LTD. fully complied with SEC requirements and smoothly completed the filing process. This result marks an important milestone in CRYPTOMMS’s compliance process and enhances its brand authority.

Headquartered in the United States, CRYPTOMMS LTD. is an AI-driven centralized cryptocurrency exchange and wallet platform, known as CRYPTOMMS. The company is committed to providing quality services to millions of customers worldwide. Recently, CRYPTOMMS announced the launch of a series of public welfare projects aimed at fulfilling social responsibilities and promoting the continuous development of the industry.

https://www.sec.gov/edgar/browse/?CIK=2024131

CRYPTOMMS LTD. actively fulfills its social responsibilities by engaging in various forms of public welfare activities. The company not only donates urgently needed supplies to impoverished communities but also actively participates in environmental protection and sustainable development projects. Additionally, CRYPTOMMS strongly supports education by providing AI-enabled electronic devices to schools in poor areas, using AI technology to improve educational conditions.

The CRYPTOMMS team brings together outstanding blockchain technology experts from around the world, with core members having worked at globally renowned fintech companies. With business operations spanning over 30 countries, CRYPTOMMS has established a good reputation in many countries through innovative products, exploring new trading methods, and providing quality services.

To fulfill its social responsibilities, CRYPTOMMS has undertaken the following public welfare activities:

• Donated AI-enabled electronic devices to schools in impoverished areas.

• Conducted lectures to popularize knowledge of blockchain technology and AI.

• Promoted the application of blockchain technology in green energy management and carbon emission monitoring.

• Provided funding to inspire young people’s interest in blockchain and AI technologies.

• Announced that a portion of its revenue would be donated to charitable organizations to support various social welfare causes, improve social welfare, and promote social equity.

The core of the CRYPTOMMS trading system lies in its powerful data analysis and processing capabilities. Utilizing technologies such as machine learning and deep learning, the CRYPTOMMS trading system can continuously learn and optimize trading strategies, thereby improving the accuracy and efficiency of trading. The system can automatically execute trades and operate according to preset rules, reducing human factors in trading decisions and enhancing trading stability and consistency.

The CRYPTOMMS AI intelligent trading system uses automated methods to acquire and analyze massive amounts of market data to better capture market changes. The system can monitor market dynamics in real-time, identify potential trading opportunities, and respond quickly. Compared to traditional manual trading, the AI intelligent trading system has faster decision-making speed and a broader range of information coverage, enabling more accurate market insights.

Driven by the AI wave, CRYPTOMMS actively participates in promoting informatization in impoverished areas. The company provides laptops and smartphones to these regions, supports financial inclusion projects, and offers technical support, enabling local residents to access online financial and other network resources. This not only helps those who lack access to traditional financial services but also promotes financial inclusion and sustainable development.

Through these efforts, residents of impoverished areas are integrated into the information society and have the opportunity to learn about AI and blockchain technology. Meanwhile, CRYPTOMMS has carried out a series of digital literacy training activities to improve the information literacy of local residents. These initiatives aim to promote the development of AI and financial inclusion, allowing more people to enjoy the benefits and opportunities brought by AI and blockchain, contributing to the construction of an information society.

CRYPTOMMS hopes to fulfill its social responsibilities through these public welfare activities, contribute to industry development, and benefit more people.

Media Contact
Company Name: CRYPTOMMS LTD.
Contact Person: JOSEPH C KILRAIN
Email: Send Email
Country: United States
Website: https://office.cryptomms.com

LiTime Announces 2024 Prime Day Event Amid Global Energy Transition

Shenzhen, China – Renowned for its lithium iron phosphate (LiFePO4) batteries, energy brand LiTime has announced the launch of its 2024 Prime Day event. This initiative, aimed at promoting new energy storage solutions and enhancing user benefits, will run from July 16 to July 17. During this period, customers can log into the LiTime website to enjoy Amazon Prime-like prices without needing an Amazon Prime membership. Additionally, the LiTime website will offer double points for eligible purchases to its valued website members.

Global Energy Transition

According to the World Meteorological Organization’s (WMO) 2023 State of the Global Climate report, the growth rate of renewable energy capacity worldwide has reached its highest speed observed in the past two decades, marking the beginning of a substantial energy transition. While harnessing renewable energy from nature is crucial, efficiently and reliably storing this energy is equally important. Lithium iron phosphate, a chemical material used in manufacturing lithium-ion batteries, is renowned for its high safety, efficiency, and environmental friendliness. It is suitable for renewable energy, household, and portable electronic device storage, making it widely applicable for personal use.

Versatile Application Needs

Beyond understanding the inherent advantages of lithium iron phosphate, individuals may encounter various scenarios when using batteries made from this material, such as water-based, land-based, and household scenarios. LiTime, driven by user needs, has designed and developed multiple lithium iron phosphate batteries suitable for different scenarios to meet diverse user requirements.

For Water-Based Scenarios: 12V 100Ah TM Battery for Trolling Motors

  • Prime Day Price: $254.98 (Original Price: $539.99, 47% Discount)

  • Description: Designed for avid fishing enthusiasts, this battery provides quick and reliable power delivery for trolling motors. Engineered for harsh environments, it features an IP65 waterproof rating and 1280Wh of usable energy, suitable for 30-70 lbs trolling motors. It supports a maximum discharge current of 300A to 500A for 5 seconds, ensuring smoother and more precise control of trolling motors for more effective fishing.

  • Other recommended batteries for this scenario:

o Motor thrust 70-100 lbs: 24V 100Ah Bluetooth $531 (Original Price: $869.99, 61% Discount)

o Motor thrust 100-120 lbs: 36V 55Ah TM $449.99 (Original Price: $666.66, 67% Discount)

For Land-Based Scenarios: 12V 100Ah Group24 Bluetooth Battery for RVs

  • Prime Day Price: $279.99 (Original Price: $579.99, 48% Discount) 

  • Description: Designed for professional RV travelers, this battery reduces storage space by up to 25% compared to a 12V 100Ah lead-acid battery while delivering 200% more energy. Paired with LiTime’s intelligent Bluetooth 5.0, it allows real-time monitoring of the battery’s overall status and data through the LiTime app, including SOC, charge/discharge/idle status, voltage, current, power, remaining capacity, temperature, and life cycle.

  • Other recommended batteries for this scenario:

o 12V 230Ah Plus, Low-Temp $557.99 (Original Price: $849.99, 65% Discount)

o 12V 280Ah Plus, Low-Temp $638.99 (Original Price: $1014.27, 62% Discount)

o 12V 460Ah $1199.99 (Original Price: $2099.99, 57% Discount)

o For larger RVs, higher voltage batteries are needed: 24V 230Ah $1999.99 (Original Price: $1119.99, 55% Discount)

For Home Energy Storage: 51.2V 100Ah Battery

  • Prime Day Price: $1259.99 (Original Price: $2169.99, 58% Discount)

  • Description: Providing a practical solution for off-grid living, this battery offers 5120Wh of energy and supports 4P, utilizing premium lithium cells to store a large amount of clean energy. It can power a 120W refrigerator continuously for 42.6 hours. LiTime is committed to providing safe and green power systems, with a product design that emphasizes environmental friendliness, contributing to the reduction of carbon emissions even in household power use.

New Product Announcements

LiTime, with a robust R&D team, is a truly user-driven innovation brand. Based on feedback from over 30,000 users, they have developed more multi-scenario batteries, providing users with more efficient and environmentally friendly energy solutions.

New 12V 100Ah Marine Outboard Motor Battery

  • Description: Designed to support 5P5S configurations, this versatile battery is expandable to suit 24V, 36V, 48V, and 60V electric outboard motors. Featuring EV Grade-A cells, one unit of this battery is equivalent to two 12V 100Ah lead-acid batteries. It fits the Group31 size, seamlessly matching the original battery tray on boats for effortless replacement of old lead-acid batteries. The battery is equipped with the latest upgraded LiTime 5.0 Bluetooth system, allowing automatic connection to smartphones for real-time monitoring of battery status and data.

New 51.2V 100Ah Complex Home Storage Battery

  • Description: Upgraded from the original home storage battery, this model is more suitable for home energy storage. Its 3U server rack cabinet and customized stacking components save home storage space while being sturdier and easier to install. Designed with home use in mind, it features an intelligent touch screen and LED status lights. Its communication capabilities are seamlessly integrated with household usage, supporting industrial communication standards such as CANbus/RS485, and ensuring compatibility with a wide range of integrated MPPT charge controllers available in the market.

About LiTime

Originating from Shenzhen, China, LiTime has been a pioneer in the new energy storage field for over 15 years. Centered on user needs and driven by technological innovation, LiTime continually breaks new ground to provide the best value lithium iron phosphate batteries. As a leader in the industry, LiTime is dedicated to delivering green, sustainable, and efficient energy solutions while contributing to the reduction of the global carbon footprint and transforming the power grid landscape.

Media Contact
Company Name: Shenzhen LiTime Technology Co., Ltd
Contact Person: Shafee Chang
Email: Send Email
Country: China
Website: https://www.litime.com/

Instant Restaurant Websites Introduces Smart Solution for Restaurant Owners to Attract More Customers

New Platform Boosts Online Visibility and Reduces Costs for Restaurants

Instant Restaurant Websites has launched a new platform designed to help restaurants enhance their online presence affordably. This service allows restaurant owners to create professional, feature-rich websites in minutes, addressing the challenge of maintaining an affordable online presence in the hospitality industry.

The increasing importance of a strong online presence for restaurants has become evident in recent years. Being ranked at the top of Google is critical to the success of any local restaurant. However, many restaurant owners find professional web design services prohibitively expensive, putting them at a disadvantage in the digital marketplace. Instant Restaurant Websites aims to bridge this gap by providing an accessible, user-friendly tool that makes effective digital marketing attainable for restaurants of all sizes.

William Chase, CEO of Instant Restaurant Websites, explained the company’s mission: “We’ve seen firsthand how smaller restaurants struggle to compete online. Our goal is simple: give every restaurant the chance to shine on the web, regardless of their tech skills or budget. It’s about leveling the playing field and helping good food find its audience.”

The Instant Restaurant Websites platform offers a range of features tailored to the restaurant industry:

● Quick setup process, allowing restaurants to launch their sites rapidly

● Choose from ready-made restaurant websites that are customized to your needs

● Restaurants pay a small monthly subscription fee instead of forking over thousands of dollars to a web design company

● Cost-effective alternative to traditional web design services

● Essential features including online menus, reservation systems, and mobile-friendly designs

● Built-in SEO tools to improve search engine visibility

● User-friendly interface suitable for those with limited technical knowledge

● Ongoing updates and support to keep websites current and effective

This platform is particularly valuable for independent restaurant owners and small chains who have previously found it challenging to establish a meaningful online presence due to limited resources. It also offers an efficient solution for marketing professionals looking to quickly enhance their clients’ digital visibility in the competitive food service sector.

The real-world impact of the platform is already evident. James Chen, owner of Spice Fusion in Portland, OR, shared his experience: “As a small business owner, I was always putting off getting a proper website because of the cost. Instant Restaurant Websites changed that for us. We now have a professional-looking site that actually brings in customers. It’s made a real difference to our bottom line.”

Looking ahead, Instant Restaurant Websites plans to continue refining its offerings. The company is exploring partnerships with food delivery services and developing more advanced analytics tools to help restaurant owners better understand and cater to their customers’ preferences.

For restaurant owners interested in boosting their online presence, more information is available at www.instantrestaurantwebsites.com.

About Instant Restaurant Websites:

Instant Restaurant Websites was born out of a simple idea: every restaurant deserves a great online presence, regardless of budget. Founded in 2023 by William Chase, a veteran web developer and food enthusiast, the company bridges the gap between high-end web design and the real needs of local eateries. They’ve streamlined the website creation process, making it both affordable and user-friendly. The team combines expertise in web technology with a deep understanding of the restaurant industry, ensuring that each site they help create not only looks good but also drives real business results. At Instant Restaurant Websites, they’re not just building websites – they’re helping to level the digital playing field for restaurants of all sizes.

Media Contact
Company Name: William Chase
Contact Person: William Chase
Email: Send Email
Country: United States
Website: http://www.instantrestaurantwebsites.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Instant Restaurant Websites Introduces Smart Solution for Restaurant Owners to Attract More Customers

The Christian in the Cult – And How to Discover Humanity in Christ, By Jim Valekis

Kharis Publishing announces the release of The Christian in the Cult: And How I Discovered Humanity in Christ, by Jim Valekis. He uses his life story to take readers deep into the culture of the Greek Orthodox Church, Herbert Armstrong’s Worldwide Church of God, and modern Evangelicalism.

Jim Valekis was born in Alabama with a “bouzouki” on his knee. His Greco-American parents raised their family as part of a thriving Greek Orthodox community in Birmingham. As a teenager captivated by the radio teachings of Herbert W. Armstrong, Valekis defied his roots and eventually followed a call to pastor in the Worldwide Church of God. When the former cult transitioned into Evangelicalism, Jim followed, continuing to pastor in Grace Communion International. Most recently, Valekis co-founded the vision for the Tipp Center, a faith-based business and resource hub, where he is the chaplain. It this rich history of faith that informs Jim’s expansive and immersive narrative in The Christian in the Cult.

Jim spent 21 years in the Worldwide Church of God, a Pasadena, California-based American church many called a cult. And spent 19 years and most of his pastoral career pastoring working to transform and replant one of its churches when this cult reformed doctrinally in 1994.  He saw God turn a socially isolated commuter church into an outreaching community church, and was at least verbally acknowledged for having done so on a national website. He experienced personally what it took to transform biblically from a very non-orthodox narrow view of the Scripture to a “new covenant” biblically correct one. In the process, he learned what makes a “cult” a cult from personal experience. Jim has an amazing “insiders” story of what really happens when a universally recognized cult attempts to transform, and behind-the-scenes struggles that occur within such a culture.  He also has had personal experience with how the evangelical world has “cultural” limitations that go back to a misunderstanding of what Luther intended in the Reformation. Jim is now calling for a reformation to the Reformation and a new way for being church – not just for Protestants, but Catholics and Orthodox Christians as well.

Therefore, Jim Valekis’ The Christian in the Cult – And How I Discovered Humanity in Christ uses the author’s life story to take the reader deep inside the culture of the Greek Orthodox Church, Herbert Armstrong’s Worldwide Church of God, and modern Evangelicalism. After journeying through three versions of “the only true church,” Valekis deftly invites his readers to join him in his ongoing discovery of humanity in Christ and what it can mean for the church and the world.

Here is how Andrew Manis, Emeritus Professor of History Middle at Georgia State University, Macon, Georgia, describes The Christian in the Cult: ”Millions of religious believers will clearly recognize the spiritual journey narrated by Jim Valekis in this powerful story. A son of the Greek Orthodox Church finds himself in Herbert W. Armstrong’s Worldwide Church of God, which eventually takes him into more traditional Christianity and out again. Where he ends up at the end of this fascinating pilgrimage will be a big surprise. But Valekis astutely narrates his journey and brings readers along with him to a spiritual destination that includes the whole world. In a religious and political that has become a culture war of all against all, Valekis’s final message of oneness and wholeness in Christ is a welcome antidote.”

On his part, Chuck Proudfit, who is president of At Work On Purpose, sees Jim’s work as a testament to how faith in Jesus Christ can get one grounded and stablished spiritually despite the pains of a broken world.  According to him, “In your hands is a book that speaks powerfully to both the complexities of living and growing in the Church, and to the way God moves in our individual lives as believers. Through the story of author Jim Valekis, we see a riveting faith testimony passed from one generation of family to another — across cultures, continents and denominations. We experience through Jim’s journey how our Christian faith can ground us and cover us spiritually, despite a fallen world, broken relationships, and vocational volatility. Jim reminds us that while our conditions and surroundings rise and fall, our steadfast relationship with Christ is All. I commend this book to you.”

For Terry Wardle, Founder of Healing Care Ministries, it was the way Jim seamlessly interwove a complex personal story with historical and scriptural insights that resonated with him. According to him, “Jim Valekis has written a journey narrative that bends the reader continually toward wholeness in Christ. His writing is deeply personal, clearly theological, and thoroughly biblical, mining the depth of each discipline to unearth the force of God’s transforming love. There is in these pages a complex personal story, interwoven with historical and scriptural insights that can guide the reader through the fog of theological compromise to the clarity that comes when Christ alone is the Lord of life. It has been said that life is a journey of formation, with the looming question, “Into what am I being formed?” Jim Valekis shines an uncompromising light on the person of Jesus Christ and bids us to surrender to the formative power of his Presence, alive in the human heart.”

Jim holds a master’s degree in biblical studies from Earlham School of Religion. He enjoys hanging out with his wife Becky, biking, painting, and sharing (especially over Greek comfort food) how his new theological understanding connects back in profound ways with the ancient Trinitarian fabric of his Orthodox upbringing, a relational Christ-centered fabric expansive enough to include every human being.

Get a copy of this book at:

Amazon: https://www.amazon.com/dp/B0D5VVCJJ7

Video Link: https://www.youtube.com/embed/gWiC7In4K5E

Kharis Publishing, an imprint of Kharis Media LLC and a leading inspirational General Trade Book publisher is currently accepting unsolicited queries for nonfiction (self-help, memoirs, business, Christian, health and wellness) from qualified leaders, professionals, pastors, and ministers) for a limited time. “Write in a book what you see…” There are no guarantees, but it is worth a shot: https://kharispublishing.com/kp/query

Media Contact
Company Name: Kharis Media LLC
Contact Person: Samuel Flourish
Email: Send Email
Phone: (630) 909-3405
City: Aurora, Chicago
State: IL
Country: United States
Website: https://kharispublishing.com/kp/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Christian in the Cult – And How to Discover Humanity in Christ, By Jim Valekis

How to Count the Stars and Live in Wonder

Kharis Publishing announces the release of “Count the Stars” by Matthew Turner. Drawing from the life of Abraham, the author shares a personal account of how to lift your head high, count the stars, and live in wonder. He writes that, similar to Abram, this is the time to go outside your tent, lift your eyes to gaze into the heavens, and then do the impossible. “Count the Stars.”

Matthew Turner, the author of the newly released book, Count the Stars, discusses the importance of taking time to gaze into the heavens in wonder, no matter the challenge. He draws inspiration from the life of biblical Abram.  In an incredible encounter with God, Abram opens his heart and shares a sincere, direct dialogue and shares his frustrations and anxieties. In shocking grace, the Lord, instead of rebuking him, calls Abram outside his tent, lifts his eyes to gaze into the heavens, and then asks him to do the impossible: Count the stars. While it was impossible for Abram to count all the stars, it was an easy task for God.

Individuals who have read the book state that it helped them to be filled with the wonder of God and His power. Others suggest that message in the book helped them to be emptied of fear and worry as they are reminded of God’s abilities. Others say that the author helped them to become grateful to have One with whom they can be honest and open. In a time when many people are leaving organized religion and abandoning regular church attendance because of concern that the demands of faith might be too restrictive, it is refreshing to see a book that helps people want to embrace God, rather than run away from Him. In fact, that was an important refrain from many people who have read the book – that “Count the Stars” made them more excited about God and the prospect of a walk of faith and hope with Him.

According to Dr. Mark Rutland, Executive Director of The National Institute of Christian Leadership, “In the unending drama of today’s culture, in the midst of modern life’s intimidating contortions, one longs for a voice of hope. Dr Matthew Turner’s newest book, Count the Stars, is a timely and a readable response, calling us to that place of intimacy with God where we can hear again, believe again and obey without fear. You’ll be blessed by this book and I recommend it.”

Here is how Dr. Sam Hemby, Professor of Leadership at the Southeastern University described his own impression of the book, “I have been a night-sky lover for a long time. Nothing is more peaceful to me than to look into the star-lit blackened backdrop of a crisp night canopy and be reminded that there is a BIG GOD… and I’m not Him! Dr. Turner’s wonderful look into the life of Abraham and God’s patient interaction with him could not be a more timely read! The dark skies of uncertainty and difficulty are all around us. But so are the stars! As you dive into Count the Stars, you will be encouraged and transformed… you will also never look into the night sky the same again!”

When asked about the potential impact of Count the Stars, Dr. Eric Speir, Academic Director, Nelson University, was rather forthright: “Dr. Matthew Turner has written a clear, simple, and concise book on how to cut through the clutter and noise to hear the voice of God for your life. This book is a must-read for anyone wanting to experience the awe and wonder of God and to experience his plans and purposes for their lives.”

Is “Count the Stars a book for everyone? Dr. Doug Beacham, General Superintendent, International Pentecostal Holiness Church, says that the message of the book is for everyone – both laity and preachers. Here is how Beacham described the book, “Matthew Turner takes us on an insightful journey with the Biblical patriarch Abraham. You will feel yourself leaving Ur of the Chaldees, struggling with Abraham and Sarah in Egypt, wondering how God will perform His promise of a child born late in life, and looking into the night sky in amazement at the magnitude of God’s promises. This is an excellent book for laity and preachers alike as we grow in our walk with the same God who called Abraham four thousand years ago. You will hear that same divine voice calling you to the exciting journey of faith.”

Dr. Matthew Turner, ordained minister, is a follower of Jesus, a husband, and father who has pastored and held multiple ministry leadership roles. He has authored several books including: Follow Him and Discipleship Journey. He also is an instructor at the Barnett College of Ministry and Theology at Southeastern University. Matthew has a BA from Jacksonville State University, a MA from Liberty University, and a DM from South University. Matthew has been married for fourteen years to his sweetheart, Anna Kate, and they have three children, Elia Kate, Edyth Ray, and Ephraim Franklin.

“Count the Stars” is available wherever books are sold, including:

Kharis Website: https://kharispublishing.com/kp/product/count-the-stars/

Amazon: https://www.amazon.com/dp/B0D68RG3D7

ABOUT KHARIS PUBLISHING

Video Link: https://www.youtube.com/embed/gWiC7In4K5E

Media Contact
Company Name: Kharis Media LLC
Contact Person: Samuel Flourish
Email: Send Email
Phone: (630) 9093405
City: Aurora, Chicago
State: IL
Country: United States
Website: https://kharispublishing.com/kp/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: How to Count the Stars and Live in Wonder